NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04009317,Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT04009317,,UNKNOWN,To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.,NO,ALK-positive NSCLC,DRUG: TQ-B3139|DRUG: Crizotinib,"Progression-Free Survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 36 months","Objective Response Rate (ORR), Percentage of subjects achieving complete response (CR) and partial response (PR)., up to 36 months|Disease Control rate (DCR), Percentage of subjects achieving CR, PR, stable disease (SD) and Non-CR/Non-progressive disease (PD), up to 36 months|Overall Survival (OS), OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 36 months",,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,260,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,TQ-B3139-III-01,2019-08-13,2021-10-30,2022-04-30,2019-07-05,,2019-10-30,"Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510050, China",
